Xolair Now Available in Pharmacies: A Breakthrough for Patients with Chronic Spontaneous Urticaria (CSU) in Lombardy

Starting August 4, 2025, a new simplified process for prescribing and dispensing the biological drug omalizumab (Xolair), used in the treatment of Chronic Spontaneous Urticaria (CSU), is now active in Lombardy.

This innovation marks a major step forward in improving the quality of life for CSU patients by making access to treatment easier, faster, and more efficient.

Thanks to the collaboration between healthcare professionals, regional health authorities, and ARCO Association, patients can now benefit from:

• Paper-Based Therapeutic Plan (PT): Replaces the outdated AIFA registry for initial prescriptions. The PT is valid for one year and provided directly to the patient.

• Electronic Prescription (DEM): The general practitioner can issue an electronic prescription based on the PT provided by the specialist.

• Pharmacy Pickup via DPC (Distribution on Behalf): Patients can now collect Xolair directly from their local pharmacy, without the need for hospital visits.

This new system applies to both new patients and those already undergoing treatment.

Direct Benefits for Patients

• Less bureaucracy: No more AIFA registry for first prescriptions.

• Fewer trips: Medication available at your trusted pharmacy.

• Time and cost savings: Avoid unnecessary travel, waiting times, and time off work.

• More availability for specialist visits: With reduced administrative burdens, specialists can dedicate more time to new patients, shortening waiting lists for CSU and other conditions.

  
  

This achievement demonstrates how collaboration, innovation, and patient-centered care can create a modern and equitable healthcare system, fully aligned with Article 32 of the Italian Constitution:“The Republic safeguards health as a fundamental right of the individual and as a collective interest.”